The benchmark Sensex gained 4,642.84 points, or 16.%, while the broader NSE Nifty surged 1,572.85 points, or 18.20% during this period.
The index rising for the fourth straight session surged 564 points.
Stocks reeled under huge losses on Thursday as the benchmark Sensex plunged sharply by over 465 points, the biggest single-day fall in three months, after India carried out "surgical strikes" on Wednesday night on terror launch pads across the Line of Control.
How did marquee Dalal Street investors fare in the Jan-Mar quarter that saw the BSE Sensex tank 10 per cent?
Aurobindo Pharma, Cadila Healthcare and Serum Institute are readying their vaccine candidates.
Top corporates have paid more advance tax in second quarter this year.
Brokerages expect Nifty50 firms to post 11.8% growth in net profit in Q1 but sales may decline
Data also show that several other leading domestic pharma companies have recalled their products from the US
GVK Biosciences is the latest Indian firm to come under international scrutiny over quality issues.
The S&P BSE Sensex dropped 207 points to end at 25,230.
Is yet to decide about the partnership or acquisition route
Traders are closely watching the progress of the monsoon.
The analysis covers BSE 200 Index's 171 companies for which data on the compensation to the boards of directors for FY14 and FY13 are available.
A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.
Next set of Q4 FY16 earnings, progress of monsoon along with election poll outcome will dictate market trend this week
Consumer businesses come to the rescue of large conglomerates in the midst of a meltdown in commodities.
Midcap stocks continued to remain on buyers' radar with BSE Midcap index up 0.1%.
TCS tops the list of 100 wealth creators for the fourth time in a row
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
Experts say the stock market correction in recent times increases the risk-reward in favour of large-cap stocks.
While gold returned 12 per cent annual gain in 10 years, Nifty didn't exceed 9 per cent.
The BSE Mid-cap index gained 1.1% while the Small-cap index surged 1.3%, outperforming the benchmark indices
Tata Consultancy Services (TCS), HCL Technologies and HDFC Bank are among the 50 best public companies in Asia-Pacific according to a compilation by Forbes, which ranked India second behind China as home to the "world's next growth engines".
The rupee resumed lower at 63.65 per dollar as against previous closing of 63.58 at the Interbank Foreign Exchange (Forex) market.
It's time for Indian generic companies to rethink their strategies.
Ajit Mishra, vice president, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.
These investors are not only betting on little-known stocks, but also sectors that the market participants are not paying much heed to. Some of these stocks can be potential multi-baggers, while others may not live up to the expectations of these stock-pickers, says Jash Kriplani.
Investors continue to make losses on investments.
'We have seen a host of businesses across sectors generate economic value and wealth for investors.'
Impact of the slowdown is most visible among promoter/owner-CEOs
Forbes said Prime Minister Narendra Modi's "economic experiments" barely affected India's billionaires while none gained more than oil-and-gas tycoon Mukesh Ambani, who cemented his decade-long hold on the top slot by adding a staggering USD 15.3 billion (67 per cent) to his last year's wealth to become one of Asia's top five richest.
Cipla, though late in changing its strategy for international markets, has in recent years taken an inorganic route for expansion.
Govt bans brands with annual sales worth Rs 3,728 crore.
Raising concern about over-dependence of Indian capital markets on foreign institutional investors, eminent banker Deepak Parekh has said that something needs to be done to change this pattern.
Besides foreign flows, corporate earnings and US Federal Reserve chief Janet Yellen's testimony to the nation's legislature are also likely to impact investor sentiment.
The 50-share NSE Nifty was trading lower by 24 points.
Not much is heard or read about Sun Pharma's media-shy owner.
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
The BSE Midcap and Smallcap indices underperformed the largecaps and ended over 1% lower.
The BSE Midcap ended up 0.5% while the Smallcap index ended nearly 1% higher
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances